|
|
|
|
| LEADER |
04569nmm a2200349 u 4500 |
| 001 |
EB000422968 |
| 003 |
EBX01000000000000000276050 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140107 ||| eng |
| 020 |
|
|
|a 9780857299109
|
| 100 |
1 |
|
|a Ledermann, Jonathan A.
|e [editor]
|
| 245 |
0 |
0 |
|a Controversies in the Management of Gynecological Cancers
|h Elektronische Ressource
|c edited by Jonathan A. Ledermann, Carien L. Creutzberg, Michael A. Quinn
|
| 250 |
|
|
|a 1st ed. 2014
|
| 260 |
|
|
|a London
|b Springer London
|c 2014, 2014
|
| 300 |
|
|
|a XV, 349 p. 44 illus., 31 illus. in color
|b online resource
|
| 505 |
0 |
|
|a 1. Controversies in the Treatment of Women with Early Stage Epithelial Ovarian Cancer -- 2. Recurrent Ovarian Cancer: When to Treat and How to Assess -- 3. New Views of Ovarian Carcinoma Types: How will this Change Practice? -- 4. Lymphadenectomy in Endometrial Cancer: The Controversy Rages Unabated -- 5. What is the Role of Adjuvant Radiotherapy and Chemotherapy in Endometrial Cancer? -- 6. Chemotherapy and/or Targeted Therapies for Advanced Endometrial Cancer: Time to Rethink? -- 7. Is Cervix Cancer a Disappearing Disease? Impact of HPV Vaccination in Developed Countries -- 8. What is the Role of Cytotoxic Chemotherapy in Advanced Cervical Cancer? -- 9. Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned? -- 10. What are the Treatment Options for Recurrent Ovarian Cancer? -- 11. How To Study Rare Gynaecological Tumours: Trials or Registries? -- 12. What is the Best Treatment Model for Gynaecological Cancers? Does Centralization Help? --
|
| 505 |
0 |
|
|a 13. When Should Surgery be Performed for the First-Line Treatment of Advanced Ovarian Cancer? -- 14. Does Intraperitoneal Therapy for Ovarian Cancer have a Future? -- 15. Maintenance Therapy for First-Line Treatment of Ovarian Cancer—Is this the Strategy for the Future? -- 16. What is the Value of Lymphadenectomy in Early Ovarian Cancer? -- 17. Sentinel Node Biopsy—Does it Help in the Management of Vulvar Cancer? -- 18. Controversies in the Management of Advanced Vulvar Cancer -- 19. Bowel Obstruction in Ovarian Cancer: To Operate or Not? -- 20. Early Cervical Cancer: Can Fertility be Safely Preserved? -- 21. What is the Role of PET/CT in Gynaecologic Cancers? -- 22. Do Intensity-Modulated Radiation, Image-Guided Radiation, and 3D Brachytherapy Significantly Advance Radiotherapeutic Management of Gynecologic Cancers? -- 23. What is the Place of Hormone Replacement Therapy in Ovarian, Endometrial, and Breast Cancer? --
|
| 505 |
0 |
|
|a 24. Familial Gynaecological Cancers: Whom to Screen and How to Manage? -- 25. TrialDesign: Should Randomized Phase III Trials in Gynaecological Cancers be Abandoned? -- 26. How Should Early Gestational Trophoblastic Disease be Managed? -- 27. Should Every Woman with Gynaecologic Cancer Undergo Routine Screening for Psychological Distress and Sexual Dysfunction? -- 28. How Should Gynaecological Sarcomas be Managed? -- 29. What is the Future of Immunotherapy in Ovarian Cancer?
|
| 653 |
|
|
|a Gynecology
|
| 653 |
|
|
|a Gynecology
|
| 653 |
|
|
|a Cancer Therapy
|
| 653 |
|
|
|a Cancer / Treatment
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Creutzberg, Carien L.
|e [editor]
|
| 700 |
1 |
|
|a Quinn, Michael A.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 028 |
5 |
0 |
|a 10.1007/978-0-85729-910-9
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-0-85729-910-9?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a Gynecological cancers are some of the most commonly occurring malignancies in women. Despite their high incidence, treatment and management of these cancers remain controversial, with conflicting evidence about many aspects of the disease. Controversies in the Management of Gynecological Cancers offers a unique assessment of the opposing sides of the controversial issues associated with gynecological cancers, and aims to provide professionals in the field with a keener sense of the underlying evidence-base and a starting point from which to follow the ongoing debate. A section on the direction of future research to resolve these issues completes the discussion in each chapter. This book will appeal to specialists, trainees and healthcare workers in gynecological oncology, gynecologists, medical oncologists and radiation oncologists, and is an excellent starting point for anyone who wishes to gain a better understanding of the complex nature of the management of gynecological malignancy.
|